“LEQEMBI(R)” (lecanemab) IV Repairs Dosing for the Therapy of Early Alzheimer’s Disease Popular in the United Kingdom

TOKYO and CAMBRIDGE, Mass., Nov 14, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced this present day that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic establish: lecanemab) has been popular for as soon as every four weeks intravenous (IV) upkeep dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.In August 2024…
Read Extra